Table 5.
Final Multivariate Analysis Model of the Association of Use of HRT With CRC in Peri/Postmenopausal Female MECC Study Participants
| Variable | Peri/Postmenopausal Females (unconditional; n = 1,982) |
||
|---|---|---|---|
| OR | 95% CI | P | |
| HRT use, ever | 0.37* | 0.22 to 0.62 | |
| Aspirin use, daily, 3+ years | 0.60* | 0.45 to 0.79 | |
| Statins use, 5+ years | 0.51 | 0.36 to 0.73 | |
| Family history of CRC, first degree | 1.79 | 1.32 to 2.45 | |
| Sports activity | 0.52 | 0.41 to 0.65 | |
| Vegetables, ≥ 5/d | † | ||
| Age, per year | 0.99 | 0.98 to 0.998 | |
| HRT × aspirin | 3.55 | 1.42 to 8.86 | .007 |
| HRT × sports | 2.25 | 1.15 to 4.38 | .017 |
NOTE. Odds ratios shown for variables in final model only.
Abbreviations: MECC, Molecular Epidemiology of Colorectal Cancer; HRT, hormone replacement therapy; CRC, colorectal cancer.
*
This model includes an interaction of HRT × aspirin, therefore the aspirin effect is among non-HRT users and the HRT effect is among non-aspirin users.
†
Dropped out of final model.